---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069124"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:47:34.655811+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma Q1 net loss $12.3M; announces BI collaboration for CUE-501 and $20M capital raise

## Summary
- Net loss $12.3M ($0.17 EPS) vs $12.3M ($0.25) YoY; revenue $0.4M down from $1.7M.
- Announced Boehringer Ingelheim collaboration for CUE-501: $12M upfront + up to $345M milestones.
- Raised ~$20M gross in follow-on capital raise; received $12M BI upfront in April 2025.
- Regained worldwide rights to lead autoimmune program CUE-401; virtual event May 15 with KOLs.
- R&D spend $8.5M vs $10.2M YoY; G&A flat at $4.2M; cash $13.1M at Mar 31.

## SEC filing metadata
- accession: 0000950170-25-069124
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000095017025069124/0000950170-25-069124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000095017025069124/cue-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069124
- JSON: https://secwatch.observer/filing/0000950170-25-069124.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069124.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.